Asia-Pacific Gastrointestinal Drugs Market 2018 Major Key Vendors - Abbott, Allergan Plc, AstraZeneca and Eli lilly Company Forecast 2023

Market Scenario
Gastrointestinal (GI) diseases affects stomach, large intestine and rectum, small intestine, esophagus, liver, gallbladder, and pancreas. The symptoms of GI diseases are heartburn, indigestion, bloating, constipation, and many more. The diseases of gastrointestinal have become common in the people across world. Gastrointestinal diseases are caused by various reasons such as acid reflux, heartburn, indigestion, nausea and vomiting, peptic ulcer disease, abdominal pain syndrome, biliary tract disorders, gallbladder disorders, and gallstone pancreatitis.
View Reports Sample @ https://www.marketresearchfuture.com/sample_request/633

Gastrointestinal diseases has gained a tremendous attention over the last few years. Owing to increasing prevalence of different gastrointestinal diseases and disorders, encouraged many companies for initiating the research in the development of innovative and advanced drugs. Furthermore, increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development drives the growth of the market. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the market growth.
From the few last decades, the government of Asian countries have been educating the people about the various diseases and their treatment availability. Relief International, with funding from the European Union, is working with Bangladesh citizens to implement One Health Asia, a program designed to prevent zoonotic diseases through training and education. Many organizations and companies are conducting surveys and programs to educate the peoples about the diseases and treatment.
Ageing, decreases the immunity of the body and increases the probability of diseases. According to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia likely to help the growth of the market over the forecast period.
On the other hand, the presence of misbranded & spurious drugs, and unavailability of lifelong cure may hinder the market growth over the review period.
The Asia gastrointestinal drugs market is expected to grow at a CAGR of 6.1% during the forecast period 2017-2023.
Check for Report Discount @ https://www.marketresearchfuture.com/check-discount/633

Segmentation
The Asia gastrointestinal drugs market is segmented on the basis of drug class and type of disease.
On the basis of drug class, it is segmented into acid neutralizers, laxatives & antidiarrheal, antiemetics, antiulcer, and others.
On the basis of type of disease, it is segmented into esophagus diseases, stomach diseases, intestinal diseases, rectum diseases, and others.

Key Findings
• The Asia gastrointestinal drugs market is expected to reach USD 20,772.4 million by 2023 at a CAGR of 6.1%
• Acid neutralizers segment accounted for the largest market share with 33.3% of the Asia gastrointestinal drug market, by drug types in 2016
• In 2016, Esophagus diseases segment accounted for the major share of the market as it was the most widely occurring GI disease. The Asia esophagus diseases market by type of diseases is expected to reach USD 7,427.6 million by 2023, growing at a CAGR of 6.32% from 2017 to 2023
• India is expected to be the fastest growing market at a CAGR of 6.60% during the forecast period
Regional Analysis
Asia gastrointestinal drugs market is segmented on the basis of region: China, India, Republic of Korea, and Rest of Asia. Japan accounts for the major share of the market owning to the well-developed technology and high healthcare expenditure. People in this region are more focused on health, which drive the growth of the market. China is the second largest market, which is followed by India. Owing to the government support for the research & development, well-developed healthcare infrastructure, and high health care expenditure drive the China gastrointestinal drugs market. India is the fastest growing gastrointestinal drugs market across the region. Increasing need for the better treatment methods rapidly changing the healthcare sector. Additionally, the presence of huge opportunities for the development of the market have boosted the market growth.
Developing nations, for instance, India is experiencing high demand for gastrointestinal disorder drugs. Major pharmaceuticals drug manufacturers are using their technology and services to develop new drugs for gastrointestinal diseases to meet the growing demand.
Key Players
Some of the key players in this market are Abbott, Allergan Plc, AstraZeneca, Eli lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals, and others.
Send An Enquiry @ https://www.marketresearchfuture.com/enquiry/633

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India

This release was published on openPR.